---
title: "Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/277870666.md"
description: "Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug"
datetime: "2026-03-05T03:14:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277870666.md)
  - [en](https://longbridge.com/en/news/277870666.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277870666.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277870666.md) | [English](https://longbridge.com/en/news/277870666.md)


# Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug



### 相關股票

- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [Hengrui Pharma (600276.CN)](https://longbridge.com/zh-HK/quote/600276.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [HENGRUI PHARMA (01276.HK)](https://longbridge.com/zh-HK/quote/01276.HK.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md)

## 相關資訊與研究

- [Hengrui Pharmaceuticals Obtains Nod for Lung Cancer Combo Drug Trials](https://longbridge.com/zh-HK/news/277871128.md)
- [Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables](https://longbridge.com/zh-HK/news/278349440.md)
- [BioVersys doses first patient in Phase 2b trial of AlpE for pulmonary tuberculosis](https://longbridge.com/zh-HK/news/278826615.md)
- [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-HK/news/278713493.md)
- [Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials](https://longbridge.com/zh-HK/news/273791098.md)